

Our Ref: DC/NB

7th March 2022

Website: www.barnsleyccg.nhs.uk
<http://twitter.com/nhsbarnsley>
www.facebook.com/nhsbarnsley

To: Prescribing Clinicians and Pharmacists within the Barnsley locality

Dear Colleague

Re: Summary of Key Points from the Area Prescribing Committee Meeting on 9th February 2022

The main outcomes of the meetings were: -

Prescribing Guidelines

The following prescribing guidelines were approved by the Committee:

Possible Alternatives to Unlicensed Specials [UPDATED] ([link](#))

The guideline has received a routine update. The table contents for each drug continue to be listed in hierarchy of risk order (the hierarchy of risk flow chart in the guideline is based on MHRA guidance). However, the information is subject to clinical interpretation and judgement on an individual patient basis and the needs and best interests of the patient should be taken into account. Manipulation of a licensed product will be outside of the product's marketing authorisation. However, there is evidence and clinical experience detailed in reputable sources (e.g. NEWT guidelines) confirming that formulation manipulation of this nature can take place without compromising the effectiveness of the medicine.

Calcium and Vitamin D (combination) and Vitamin D Summary of Formulary Choices in Adults over 18 years [UPDATED] ([link](#))

The guideline has received a routine update.

Osteoporosis Drug Holiday Guidelines for GPs [UPDATED] ([link](#))

This guideline has been updated and the following drugs have been removed:

- Ibandronic acid has been removed as this has a grey classification on the Barnsley Formulary.
- Strontium ranelate has been removed as this is a non-formulary drug (there has been a previous MHRA alert regarding cardiovascular risk).

The updated guideline on the **Management of Osteoporosis and Fragility Fracture Risk** referred to in the January memo can now also be accessed on the BEST website ([link](#)).

Prescribing guidelines are available on the BEST website:

<http://best.barnsleyccg.nhs.uk/clinical-support/medicines/prescribing-guidelines/>

The Barnsley Joint Formulary can be accessed at the link below:

<http://www.barnsleyformulary.nhs.uk/>

Shared Care / Amber-G Guidelines

The following guidelines which have been developed following the review of the corresponding formulary section were approved by the Committee:

- **Metolazone for Oedema Amber-G Guideline [NEW]**
The guideline will be available on the BEST website in due course.
- **Clomifene for the Treatment of Women with Infertility due to Ovulatory Dysfunction Amber-G Guideline [NEW]**
The guideline will be available on the BEST website in due course.
- **Desmospray® (Desmopressin Nasal Spray) for Diabetes Insipidus Amber-G Guideline [NEW] ([link](#))**
- **Amber Shared Care Guideline for Dantrolene (for the treatment of chronic severe spasticity of voluntary skeletal muscle in adults) ([link](#))**
The classification of dantrolene will be changed from Amber-G to Amber Shared Care.

Shared Care and Amber-G guidelines are available on the BEST website:

<http://best.barnsleyccg.nhs.uk/clinical-support/medicines/shared-care-guidelines/>.

Prescribers (including secondary care clinicians) are encouraged to report any problems they experience with shared care or other medicines related issues, particularly where guidelines are not being complied with, to the following email address: BarnsleyAPCReport@nhs.net.

The Barnsley Interface Issues Form should be used to report such problems:

<http://www.barnsleyccg.nhs.uk/members-professionals/area-prescribing-committee.htm>

Traffic Light Classifications

The Committee assigned the following classifications to the products included in the table below:

Drug	Formulary Indication	Traffic light status (Drugs with a provisional classification are not currently included on the Barnsley formulary)
SPS New Medicines Newsletter December 2021		
Glucagon (Ogluo®)	Treatment of severe hypoglycaemia in adults, adolescents, and children aged ≥2 years with diabetes mellitus	Non-formulary provisional grey. Administered by subcutaneous injection ONLY.
New Product Application		
Budesonide / Formoterol / Glycopyrronium (Trixeo Aerosphere®)	Maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-	Formulary green. Metered Dose Inhaler. This is a triple inhaler [containing ICS/LABA/LAMA] and should therefore not be

	acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist	used concurrently with LABA/LAMA, LABA/ICS or LAMA inhalers.
--	--	--

MHRA Drug Safety Update

The January 2022 MHRA Drug Safety Update can be accessed at the following link:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1047685/Jan-2022-DSU-PDF.pdf

There were no issues relating to primary care.

Regards



Deborah Cooke
Lead Pharmacist

cc: Medicines Management Team
Rebecca Hoskins, BHNFT
Mike Smith, BHNFT
Sarah Hudson, SWYPFT
Area Prescribing Committee Members (Secretary to the APC to circulate)
Local Medical Committee (Secretary to the LMC to circulate)
Gary Barnfield, NHS Sheffield CCG
Alex Molyneux, NHS Doncaster CCG
Stuart Lakin, NHS Rotherham CCG